Untitled

doi:10.1002/cncr.v124.1

Cited by 12 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite aggressive treatment, about 50% of patients die of their disease. 5,6 Alternative therapies are needed to improve survival while reducing treatment-associated morbidity.…”

Section: Introductionmentioning

confidence: 99%

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

et al. 2019

View full text Add to dashboard Cite

HPV16 infections are associated with a variety of cancers and there is compelling evidence that the transforming activity of HPV16 critically depends on the expression of the viral oncoproteins E6 and E7. Therapeutic cancer vaccines capable of generating durable and specific immunity against these HPV16 antigens hold great promise to achieve long-term disease control. Here we show in mice that HPV16 E7 RNA-LPX, an intravenously administered cancer vaccine based on immuno-pharmacologically optimized antigen-encoding mRNA, efficiently primes and expands antigen-specific effector and memory CD8 + T cells. HPV-positive TC-1 and C3 tumors of immunized mice are heavily infiltrated with activated immune cells and HPV16-specific T cells and are polarized towards a proinflammatory, cytotoxic and less immune-suppressive contexture. E7 RNA-LPX immunization mediates complete and durable remission of progressing tumors. Circulating memory T cells are highly cytotoxic and protect from tumor rechallenge. Moreover, E7 RNA-LPX immunization sensitizes anti-PD-L1 refractory tumors to checkpoint blockade. In conclusion, our data highlight the potential of HPV16 RNA-LPX for the treatment of HPV-driven cancers.

show abstract

“…Despite aggressive treatment, about 50% of patients die of their disease. 5,6 Alternative therapies are needed to improve survival while reducing treatment-associated morbidity.…”

Section: Introductionmentioning

confidence: 99%

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

et al. 2019

View full text Add to dashboard Cite

show abstract

“…11 A phase II study showed that the ORR was 74% and median PFS was 10 months with brain metastasis patients taking pulse-continuous dose erlotinib. 29 However, high-dosage of erlotinib will cause more serious side effects and economic effects, so it is not widely used in clinical practice. In our cases, two of the patients were treated with gefitinib at an earlier stage.…”

Section: Discussionmentioning

confidence: 99%

<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases</p>

Xu¹,

Zhou

Lü

et al. 2020

OTT

View full text Add to dashboard Cite

Leptomeningeal metastases (LM) occur in 3-5% of patients with advanced nonsmall-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.

show abstract

Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management

et al. 2021

View full text Add to dashboard Cite

IMPORTANCEThe clinical decisions that arise from prostate magnetic resonance imaging (MRI) and genomic testing in patients with prostate cancer are not well understood. OBJECTIVETo evaluate the association between regional uptake of prostate MRI and genomic testing and observation vs treatment for prostate cancer. DESIGN, SETTING, AND PARTICIPANTSThis retrospective cohort study of commercial insurance claims for prostate MRI and genomic testing included 65 530 patients 40 to 89 years of age newly diagnosed with prostate cancer from July 1, 2012, through June 30, 2019.EXPOSURES Patient-and regional-level use of prostate MRI and genomic testing. MAIN OUTCOMES AND MEASURES Observation vs definitive treatment for prostate cancer.Patient-level analyses examined the association between receipt of testing or residing in a hospital referral region (HRR) that adopted testing and observation. In regional-level analyses, the dependent variable was the change in the proportion of patients observed for prostate cancer at the HRR level

show abstract

Untitled

Cited by 12 publications

References 0 publications

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory

<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases</p>

Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management

Contact Info

Product

Resources

About